PMID- 21251982
OWN - NLM
STAT- MEDLINE
DCOM- 20120117
LR  - 20211020
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Print)
IS  - 1043-6618 (Linking)
VI  - 63
IP  - 6
DP  - 2011 Jun
TI  - Endothelins and their receptors in cancer: identification of therapeutic targets.
PG  - 519-24
LID - 10.1016/j.phrs.2011.01.002 [doi]
AB  - Endothelins and their receptors are important in normal physiology, but have been 
      implicated in various pathophysiological conditions. Members of the so-called 
      "endothelin axis" are dysregulated in a wide range of human cancers, opening the 
      door for novel anticancer therapies. Established cancer chemotherapeutic agents 
      and drugs that target specific components of the endothelin axis have been 
      combined with promising results, but more work is needed in this area. The 
      endothelin axis affects numerous signaling pathways, including Ras, mitogen 
      activated protein kinases, beta-catenin/T-cell factor/lymphoid enhancer factor, 
      nuclear factor-kappaB (NFkappaB), SNAIL, and mammalian target of rapamycin (mTOR). There 
      is much still to learn about optimizing drug specificity in this area, while 
      minimizing off-target effects. Selective agonists and antagonists of endothelins, 
      their receptors, and upstream processing enzymes, as well as knockdown strategies 
      in vitro, are providing valuable leads for testing in the clinical setting. The 
      endothelin axis continues to be an attractive avenue of scientific endeavor, both 
      in the cancer arena and in other important health-related disciplines.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Wang, Rong
AU  - Wang R
AD  - Linus Pauling Institute, Oregon State University, Corvallis, OR 97331-6512, USA.
FAU - Dashwood, Roderick H
AU  - Dashwood RH
LA  - eng
GR  - CA122959/CA/NCI NIH HHS/United States
GR  - P01 CA090890/CA/NCI NIH HHS/United States
GR  - CA90890/CA/NCI NIH HHS/United States
GR  - ES00210/ES/NIEHS NIH HHS/United States
GR  - R01 CA122959-04/CA/NCI NIH HHS/United States
GR  - R29 CA065525/CA/NCI NIH HHS/United States
GR  - R01 CA065525/CA/NCI NIH HHS/United States
GR  - R01 CA122959/CA/NCI NIH HHS/United States
GR  - CA65525/CA/NCI NIH HHS/United States
GR  - R01 CA065525-10/CA/NCI NIH HHS/United States
GR  - P01 CA090890-07/CA/NCI NIH HHS/United States
GR  - P30 ES000210/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20110118
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Endothelin Receptor Antagonists)
RN  - 0 (Endothelins)
RN  - 0 (Receptors, Endothelin)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Cell Survival/physiology
MH  - Endothelin Receptor Antagonists
MH  - Endothelins/*physiology
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Neoplasms/drug therapy/metabolism/*physiopathology
MH  - Neovascularization, Pathologic/metabolism/physiopathology
MH  - Receptors, Endothelin/agonists/*physiology
MH  - Signal Transduction/physiology
PMC - PMC3109221
MID - NIHMS266433
EDAT- 2011/01/22 06:00
MHDA- 2012/01/18 06:00
PMCR- 2012/06/01
CRDT- 2011/01/22 06:00
PHST- 2010/10/17 00:00 [received]
PHST- 2010/12/21 00:00 [revised]
PHST- 2011/01/04 00:00 [accepted]
PHST- 2011/01/22 06:00 [entrez]
PHST- 2011/01/22 06:00 [pubmed]
PHST- 2012/01/18 06:00 [medline]
PHST- 2012/06/01 00:00 [pmc-release]
AID - S1043-6618(11)00005-3 [pii]
AID - 10.1016/j.phrs.2011.01.002 [doi]
PST - ppublish
SO  - Pharmacol Res. 2011 Jun;63(6):519-24. doi: 10.1016/j.phrs.2011.01.002. Epub 2011 
      Jan 18.